Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?
Authors:
Open Access
- 24 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 725346
Abstract
Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?Keywords
This publication has 37 references indexed in Scilit:
- Sex Differences in the Drug Therapy for Oncologic Diseases2012
- Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 TrialJournal of Clinical Oncology, 2011
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008
- Role of Hematotoxicity and Sex in Patients With Hodgkin's Lymphoma: An Analysis From the German Hodgkin Study GroupJournal of Clinical Oncology, 2005
- Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- A Standard Weight Descriptor for Dose Adjustment in the Obese PatientClinical Pharmacokinetics, 2004
- Body Surface Area in Dosing Anticancer Agents: Scratch the Surface!JNCI: Journal of the National Cancer Institute, 2002
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987
- Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adultsThe Journal of Pediatrics, 1978